Highlights and Quick Summary
- Equity Repurchase (Preffered, Net) for the quarter ending December 31, 2020 was $-134 Thousand (a -100.1% decrease compared to previous quarter)
- Year-over-year quarterly Equity Repurchase (Preffered, Net) decreased by -106.8%
- Annual Equity Repurchase (Preffered, Net) for 2020 was $135 Million (a 574.3% increase from previous year)
- Twelve month Equity Repurchase (Preffered, Net) ending December 31, 2020 was $135 Million (a -12.99% decrease compared to previous quarter)
Trailing Equity Repurchase (Preffered, Net) for the last four month:
| 31 Dec '20 | 30 Sep '20 | — | — |
|---|---|---|---|
| $135 Million | $155 Million | — | — |
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Equity Repurchase (Preffered, Net) of Dyne Therapeutics, Inc.
Most recent Equity Repurchase (Preffered, Net)of DYN including historical data for past 10 years.Interactive Chart of Equity Repurchase (Preffered, Net) of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Equity Repurchase (Preffered, Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | $-0.13 | $132.95 | $0.0 | $1.97 | $134.79 |
| 2019 | $19.99 | – | – | – | $19.99 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology